logo

NUVB

Nuvation Bio·NYSE
--
--(--)
--
--(--)
5.14 / 10
Netural

NUVB's fundamentals score 5.1/10, reflecting strong interest-coverage and profit-to-market valuation but concerning revenue-to-market and inventory-turnover ratios. The Total Operating Revenue YoY growth of 873% is impressive yet unproven in cash generation, while an Inventory Turnover Ratio of 2.8088 places it in the lowest-performing quartile historically. Asset-MV and PB-ROE show moderate positives, but the negative Revenue-MV suggests valuation risk. Overall, the company's financial health is mixed, warranting cautious optimism.

Fundamental(5.14)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.57
Score1/3
Weight9.51%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value873.03
Score3/3
Weight1.77%
1M Return0.88%
Inventory turnover ratio
Value2.81
Score1/3
Weight-15.03%
1M Return-11.32%
Profit-MV
Value0.47
Score2/3
Weight22.07%
1M Return8.99%
PB-ROE
Value1.04
Score2/3
Weight29.55%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.38%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value873.03
Score2/3
Weight0.20%
1M Return0.10%
Asset-MV
Value-0.51
Score3/3
Weight35.01%
1M Return11.94%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.88%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight21.19%
1M Return8.80%
Is NUVB fundamentally strong?
  • NUVB scores 5.14/10 on fundamentals and holds a Fair valuation at present. Backed by its -42.56% ROE, -813.07% net margin, -8.99 P/E ratio, 6.00 P/B ratio, and 77.52% earnings growth, these metrics solidify its Netural investment rating.